Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$161.97 USD

161.97
575,208

+1.87 (1.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 6% (16 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

AMN Healthcare (AMN) Q2 Earnings Beat Estimates, Margins Down

AMN Healthcare's (AMN) dismal results in the majority of its segments led to a soft overall second-quarter performance.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Is DaVita (DVA) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Medical Stocks Lagging DaVita (DVA) This Year?

Here is how DaVita HealthCare (DVA) and Avadel (AVDL) have performed compared to their sector so far this year.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

DaVita (DVA) Q2 Earnings & Revenues Top Estimates, Margins Up

DaVita's (DVA) robust segmental revenues drive its second-quarter performance.

DaVita HealthCare (DVA) Q2 Earnings and Revenues Surpass Estimates

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 4.86% and 0.74%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Strength in Kidney Care Likely to Aid DaVita's (DVA) Q2 Earnings

Improvement in RPT and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the second quarter.

Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare

Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare have been highlighted in this Industry Outlook article.

Debanjana Dey headshot

4 Stocks to Watch From a Challenging Outpatient Home Health Industry

Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, EHC and ADUS are well-poised to gain.

DaVita HealthCare (DVA) Suffers a Larger Drop Than the General Market: Key Insights

In the latest trading session, DaVita HealthCare (DVA) closed at $136.47, marking a -1.93% move from the previous day.

DaVita HealthCare (DVA) Gains As Market Dips: What You Should Know

DaVita HealthCare (DVA) closed the most recent trading day at $143.81, moving +1.37% from the previous trading session.

DaVita HealthCare (DVA) Laps the Stock Market: Here's Why

The latest trading day saw DaVita HealthCare (DVA) settling at $139.96, representing a +1.46% change from its previous close.

DaVita HealthCare (DVA) Rises Higher Than Market: Key Facts

DaVita HealthCare (DVA) reachead $137.72 at the closing of the latest trading day, reflecting a +1.3% change compared to its last close.

DaVita (DVA) Gains 29.8% YTD: What's Driving the Stock?

DaVita's (DVA) shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.

Patterson Companies (PDCO) Aims to Streamline Patient Experience

Patterson Companies' (PDCO) latest integration features are likely to provide customers with additional options to streamline their experience.

Terumo (TRUMY) Unit's SOFAST Study Shows Positive Results

Terumo (TRUMY) subsidiary Microvention's SOFAST study validates the SOFIA Flow Plus Aspiration Catheter's speed, efficacy and safety in stroke thrombectomy.

Alcon (ALC) Rides on Innovation, Balanced Segmental Sales

Alcon (ALC) is witnessing growth in its over-the-counter portfolio, mainly driven by favorable pricing and a sustained family of products.

Enovis' (ENOV) New System to Aid Reverse Shoulder Prosthesis

Enovis (ENOV) introduces the AltiVate Reverse Glenoid System, expanding the glenoid implant offering of the AltiVate Reverse to include modular, augmented baseplates.

Reasons to Retain Veeva Systems (VEEV) in Your Portfolio Now

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock. However, data security threats and escalating costs are a concern.

Quest Diagnostics (DGX) Set to Acquire OhioHealth's Lab Services

Quest Diagnostics' (DGX) new agreement is likely to help expand access to cost-effective and advanced laboratory services in Ohio.

3 Reasons Why You Should Hold McKesson (MCK) Stock for Now

McKesson's (MCK) robust Biologics business raises optimism about the stock.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now

Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

Roche Holding's (RHHBY) Accu-Chek SmartGuide Receives CE Mark

Roche Holding (RHHBY) announces the receipt of CE Mark for its Accu-Chek SmartGuide CGM solution which is intended toward providing better diabetes management.

Philips (PHG) Gains Despite Recall of SENSE XL Torso Coils

Philips (PHG) issues an urgent recall of SENSE XL Torso coils (1.5T and 3.0T) due to heating risks during MRI scans.